Compare JPMorgan Equity Premium Income ETF (JEPI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Eli Lilly And Co — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.86, while Eli Lilly And Co trades at $1,222.99 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| JEPI | LLY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $1.24K |
52-Week Low | $55.29 | $639.43 |
Market Cap | — | $1.08T |
Enterprise Value | — | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.
Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
